AZ 311
Alternative Names: AZ311Latest Information Update: 18 Jan 2007
At a glance
- Originator AstraZeneca Pharmaceuticals
- Class Antispasmodics
- Mechanism of Action Neurokinin 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 06 May 2003 Preclinical trials in Overactive bladder in Canada (unspecified route)